Staged percutaneous coronary intervention and minimally invasive valve surgery: Results of a hybrid approach to concomitant coronary and valvular disease  by Santana, Orlando et al.
Acquired Cardiovascular Disease Santana et al
A
C
DStaged percutaneous coronary intervention and minimally invasive
valve surgery: Results of a hybrid approach to concomitant coronary
and valvular diseaseOrlando Santana, MD,a Michael Funk, MD,a Carlos Zamora, MD,a Esteban Escolar, MD,a
Gervasio A. Lamas, MD,a and Joseph Lamelas, MDbFrom th
Surge
Disclosu
Receive
public
Address
Colum
ton R
0022-52
Copyrig
doi:10.1
634Background:We compared a hybrid approach combining staged percutaneous coronary intervention (PCI) and
minimally invasive valve surgery with concurrent valve surgery plus bypass via a median sternotomy approach.
Methods: We retrospectively evaluated 65 consecutive patients with coronary disease and surgical valvular
heart disease who underwent planned PCI followed within 60 days by minimally invasive valve surgery, and
we compared them with 52 matched control patients who underwent conventional bypass grafting and valve
surgery.
Results: There were no in-hospital deaths in the hybrid group, compared with 2 (3.8%) observed in the matched
group (P¼ .11). Death, renal failure, or stroke occurred in 1 (1.5%) in the hybrid group versus 15 (28.8%) in the
conventional group (P ¼ .001). The median number of days between PCI and surgery was 24 (interquartile
range, 2.5-37). At surgery, 23 hybrid patients were receiving both aspirin and clopidogrel;, 18, clopidogrel alone;
4, aspirin alone; and 22 stopped the antiplatelet agents 5 days before the operation. Intensive care unit hours and
total hospital length of stay, including PCI stay for the hybrid group, were less in the hybrid group (P¼ .001 for
both comparisons). In the hybrid group, average blood use was 1.6  1.6 U per patient versus 1.9  2.4 U per
patient with conventional surgery (P¼ .35. There were no reoperations for postoperative bleeding in the hybrid
group compared with 2 (3.8%) in the conventional group (P ¼ .43).
Conclusions: Staged PCI with minimally invasive valve surgery may offer an alternative to coronary bypass
grafting with concurrent valve surgery and should be tested prospectively. (J Thorac Cardiovasc Surg
2012;144:634-9)Coronary artery bypass graft (CABG) with concomitant
valve surgery has a higher mortality than does isolated valve
surgery or isolated CABG.1-3 Typically, patients are sicker,
operative times are longer, and morbidity and mortality are
increased. Thus, some groups have begun exploring
a strategy to dissociate the procedures into 2 smaller,
staged procedures—minimally invasive valve surgery
and percutaneous coronary intervention (PCI). When
compared with a standard median sternotomy approach,
the potential benefits of minimally invasive valve surgery
include less trauma and faster recovery time, possibly
leading to improved outcomes.4-14 Inasmuch as PCI has
a mortality of less than 1% in elective settings and
minimally invasive valve procedures have a mortality
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The Journal of Thoracic and Cardiovascular Surgcombines PCI with minimally invasive valve surgery is
worthy of consideration.16-20 We report our experience
using this staged method in a nonrandomized, but
consecutive, case series.
METHODS
After obtaining approval from the institutional review board, we retro-
spectively reviewed the medical records of 65 consecutive patients with
concomitant coronary and valvular disease who underwent staged PCI fol-
lowed, within 60 days, by minimally invasive valve surgery between Feb-
ruary 2009 and June 2011. Their outcomes were compared with a matched
control group of 52 patients who underwent simultaneous conventional
CABG and valve surgery, necessarily by median sternotomy, between
March 2005 and June 2011. Excluded were patients who underwent aortic
root replacement, had active endocarditis, had left main coronary artery
disease, or underwent emergency surgery. All median sternotomy opera-
tions were performed by a group of 6 surgeons. All minimally invasive op-
erations were performed by 1 of the 6 surgeons. The median sternotomy
control group was matched on the basis of decade age, number of diseased
coronary vessels, gender, creatinine level, type of valve surgery, and heart
failure. The definitions and variables selected were based on The Society of
Thoracic Surgeons Database definitions. Composite surgical complications
were defined as the presence of postoperative renal failure, stroke, myocar-
dial infarction, or death. The hybrid patients were evaluated in the outpa-
tient setting 30 days after the operation.
Patient Selection
In all patients the coronary and valvular lesions were documented by di-
agnostic catheterization and echocardiography. The patients were selectedery c September 2012
Abbreviations and Acronyms
CABG ¼ coronary artery bypass grafting
IQR ¼ interquartile range
PCI ¼ percutaneous coronary intervention
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and/or by the surgeon.
Procedural Staging
Once the treatment plan was established, the interventional cardiologist
proceeded with PCI and possible stent placement of the coronary artery le-
sion or lesions. In all patients receiving stents, a loading dose of 600 mg of
clopidogrel and 325 mg of aspirin was administered at the time of stent
placement, followed by clopidogrel 75 mg/day and aspirin 325 mg/day
thereafter. Management of antiplatelet therapy between the PCI and the op-
eration was at the discretion of the interventional cardiologist.
Technique for Minimally Invasive Valve Surgery
All patients were placed in the supine position and underwent anesthetic
induction and intubation with a single-lumen endotracheal tube and a bron-
chial blocker. A roll was placed underneath the right scapula in patients un-
dergoing a minimally invasive mitral valve procedure. Every patient had
a Swan-Ganz catheter (Edwards LifeSciences, Irvine, Calif) and a radial
arterial line placed. A transesophageal echocardiogram Doppler probe
was placed intraoperatively to evaluate the diseased valves, as well as to
assess the postoperative results.
In all cases except 1, a femoral platformwas used to establish cardiopul-
monary bypass. A 2- to 3-cm incision was made in the inguinal crease. A
5-0 Prolene polypropylene purse-string suture (Ethicon, Inc, Somerville,
NJ) was placed on the femoral artery and vein. After heparinization, a Sel-
dinger technique was used to cannulate the femoral vessels. The femoral
artery was cannulated with a 16F to 18F arterial cannula (Edwards Life-
sciences), and the femoral vein. Transesophageal echocardiography was
used to aid in placement of the venous cannula in the superior vena cava.
For the mitral valve procedures, a 4- to 5-cm skin incision was made in
the fourth to fifth intercostal space at the site of the anterior axillary line.
The same incision was made for patients having double valve surgery in-
volving the mitral and tricuspid valves. For the mitral valve repair and re-
placements, the mitral valve was accessed through the Waterston groove
and then through the atrial septum into the left atrium. A specially designed
atrial lift retractor and atrial exposure device was used for visualization of
the mitral valve. Mitral valve repair or replacement was carried out in the
standard fashion. A 4-0 Prolene polypropylene suture was used to close the
left atrium.
In the patients undergoing mitral valve surgery with a history of CABG,
we used moderate-to-deep hypothermia (24C-26C) and fibrillatory ar-
rest. Cardioplegic solution was not delivered at all. Air was removed via
a vent placed through the atriotomy, mitral valve, and into the left ventricle.
If significant peripheral vascular diseasewas present in patients undergoing
mitral valve procedures, then axillary artery cannulation was performed, as
was the case in 1 patient of our study.
For aortic valve procedures, a 4- to 5-cm transverse parasternal incision
was made over the second to third intercostal space. This incision was ex-
tended to 6 to 7 cm in those undergoing combined aortic and mitral valve
surgery. In all aortic valve procedures, the second or third costochondral
cartilage was transected to allow adequate exposure of the aorta. At the
completion of the operation, the rib was reattached to the sternum with
a 1-cm metal plate (Synthes, West Chester, Pa) and a fiber wire was placed
in a figure-of-8 fashion. In all cases, the pericardium was opened above the
phrenic nerve and over the aorta to facilitate exposure. A transverseThe Journal of Thoracic and Caaortotomy was performed for exposure of the aortic valve. Valve replace-
ment was carried out under direct vision by standard techniques. In aortic
valve procedures, a left ventricular vent was inserted into the left ventricle
via a purse-string suture in the right superior pulmonary vein.
In patients undergoing aortic valve replacement who have a previous
CABG and a patent left internal thoracic graft, we use moderate hypother-
mia (28C) with one induction dose of antegrade cardioplegic solution.
Thereafter, cardioplegic solution is delivered retrogradely at 20-minute in-
tervals. We do not dissect the left internal thoracic artery pedicle. In the set-
ting of a patent left internal thoracic artery, we prefer the native left anterior
descending artery to be totally occluded. This diminishes a constant stream
of blood return from the left main coronary artery obscuring the operative
field. If the left anterior descending artery is patent, we place a No. 10F red
rubber catheter, connected to a pump suction, into the left main coronary
artery to aspirate the blood. If significant peripheral vascular disease had
been present, then central aortic cannulation would have been performed,
but this was not the case in any of the patients.
With transesophageal echocardiography guidance, a retrograde coro-
nary sinus catheter was directly inserted through the incision, and
a purse-string suture was placed in the right atrium. Cardiopulmonary by-
pass was initiated at 32C to 36C using a closed membrane oxygenator
and roller pump. Venous drainage was augmented with vacuum assistance
applying negative pressures of 30 to 70 mm Hg as needed to decompress
the right side of the heart. Transincisional direct aortic crossclamping was
performed with a flexible and retractable shaft crossclamp (Novare Surgi-
cal Systems, Cupertino, Calif). One dose of antegrade cold blood cardio-
plegia was given to establish electromechanical arrest of the heart.
Thereafter, retrograde cold blood cardioplegia was given throughout the
procedure at 20- to 25-minute intervals. If retrograde cardioplegia was
not possible, a cannula was left in the ascending aorta to deliver antegrade
cardioplegia, or the heart was fibrillated. All procedures were performed
with specially designed long-shafted minimally invasive instruments
(Geister, Tuttlingen, Germany). Carbon dioxide was infused into the op-
erative field during the entire procedure. Air was removed from the heart
with a needle in the root of the aorta and under transesophageal echocar-
diographic guidance. The heart was not directly manipulated during
deairing maneuvers. If needed, external compression of the chest wall
was performed to aid in deairing. With the heart empty, both atrial and
ventricular pacing wires were placed. After cardiopulmonary bypass
had been discontinued and protamine administered, decannulation was
performed. The purse-string sutures were tied, and the femoral artery
was directly repaired with 5-0 Prolene polypropylene suture. A single
chest tube was left in the pleural space. For pain relief, all patients had
an On-Q pain relief system inserted (I-Flow Corporation, Lake Forest,
Calif). Two catheters were placed in the intercostal space to deliver
0.25% bupivicaine for 72 hours. The thoracotomy incision was closed
in the routine fashion.
Statistical Analysis
All continuous variables are expressed as the means  1 standard devi-
ation. Nonparametric variables were expressed as medians and interquar-
tile ranges (IQRs, or 25% to 75%). An independent t test was used to
compare continuous variables between groups that had a normal distribu-
tion. Nonparametric variables were compared with a Mann-Whitney
U test. All dichotomous variables were compared by c2 analysis. The sta-
tistical analyses were done using SPSS version 17 (SPSS, Inc, Chicago, Ill).RESULTS
From February 2009 to June 2011, 65 patients underwent
staged PCI followed by elective minimally invasive valve
surgery. There were 37 (57%) men and 28 (43%) women
with a mean age of 75.4  8 years. The baselinerdiovascular Surgery c Volume 144, Number 3 635
TABLE 1. Patient baseline characteristics
Variables
Hybrid
group
(n ¼ 65)
Conventional
group
(n ¼ 52)
P
value
Variables
Age (mean  1 SD) 75.4  8 73.8  8.2 .3
Gender (male) 37 (57%) 29 (55%) .9
EF (mean  1 SD) 53.9  12.5% 50  12.6% .036
Prior MI 19 (29%) 11 (21.2%) .32
BMI (mean  1 SD) 27.8  4.6 27.2  4.5 .46
Diabetes mellitus 25 (38%) 15 (28.8%) .28
Hypertension 55 (85%) 49 (94%) .1
COPD 16 (25%) 16 (30.8%) .46
CHF 24 (37%) 26 (50%) .15
CVA 11 (17%) 5 (9.6%) .25
Preoperative creatinine level
(mean  1 SD)
1.21  1.1 1.16  0.49 .56
Previous CABG surgery 5 1 .16
Previous AVR 2 0 .06
EuroSCORE (mean  1 SD) 10  8.45% 8.9  4.84% .7
Preoperative medications
Aspirin 43% 44% .7
Clopidogrel 64% 17% <.001
ACE inhibitors/ARB 67% 42% .003
Nitrates 5% 7% .76
Beta-blockers 67% 73% .24
Statins 71% 64% .49
Warfarin 10% 23% .04
SD, Standard deviation; EF, ejection fraction; MI, myocardial infarction; BMI, body
mass index; COPD, chronic obstructive pulmonary disease; CHF, congestive heart
failure; CVA, cerebrovascular accident; CABG, coronary artery bypass grafting;
AVR, aortic valve replacement; ACE, agtiotensin converting enzyme; ARB, angioten-
sin II receptor blocker.
TABLE 3. Antiplatelet therapy of hybrid patients at time of cardiac
valve surgery
N ¼ 65 (%)
Antiplatelet agents stopped 5 days before surgery 20 (30.7%)
Aspirin alone 4 (6.1%)
Clopidogrel alone 18 (27.7%)
Aspirin and clopidogrel l23 (35.4%)
Any clopidogrel 41 (63%)
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tional groups, with the exception that the ejection fraction
was slightly lower in the conventional group (53.9% 
12.5% vs 50%  12.6%; P ¼ .036) and there were more
patients with a history of cardiac surgery in the hybrid group
than in the conventional group (7 [10.7%] vs 1 [1.9%], al-
though the difference did not reach statistical significance;
P ¼ .06). The EuroSCORE predicted operative mortality
was 10%  8.45% and 8.9%  4.84% for the hybrid
and the conventional groups, respectively (P ¼ .7;
Table 1). There was also no significant difference in the
number of diseased vessels of the hybrid group versus the
conventional group (Table 2).
All hybrid patients were clinically stable for both PCI
and surgery, except for 2 patients whose PCI wasTABLE 2. Comparison of the number of diseased vessels between the
hybrid and the conventional group
No. of diseased
vessels
Hybrid group
(n ¼ 65)
Conventional group
(n ¼ 52) P value
1 36 (55.3%) 29 (42%) .56
2 15 (23.1%) 29 (42%) .48
3 14 (21.5%) 11 (16%) .96
636 The Journal of Thoracic and Cardiovascular Surgperformed in the setting of an ST-elevation myocardial in-
farction and underwent minimally invasive surgery elec-
tively later. Of the 7 patients with a history of cardiac
surgery, 5 had previous CABG and underwent mitral valve
repair for severe functional mitral regurgitation and 2 had
a history of aortic valve replacement with CABG and
now had severe paravalvular aortic insufficiency needing
repeat aortic valve replacement.Description of PCI
In the hybrid arm, 36 (55.3%) patients underwent
1-vessel, 15 (23.1%) underwent 2-vessel, and 14 (21.5%)
underwent 3-vessel PCI. Drug-eluting stents were placed
in 36 (55.5%), bare metal stents in 25 (38.5%), and balloon
angioplasty was performed in 4 (6.2%). The anatomic loca-
tions of the lesions treated with PCI were as follows: 21
(32.3%) proximal left anterior descending coronary artery,
40 (61.5%) mid–left anterior descending coronary artery,
26 (40%) right coronary artery, and 21 (32.3%) circumflex
coronary artery. There were 2 post-PCI procedural compli-
cations. A femoral arteriovenous fistula, which needed re-
pair, developed in 1 patient, and a groin infection, which
was treated with antibiotics, developed in the other. Theme-
dian number of days between PCI and surgery was 24 (IQR,
2.5-37).Description of Surgery
At the time of surgery in the hybrid group, 23 (35.4%)
patients were receiving both aspirin and clopidogrel, 18
(27.7%) were taking clopidogrel alone, 4 (6.1%) were tak-
ing aspirin alone, and 20 (30.7%) patients had their antipla-
telet agents stopped 5 days before surgery (Table 3). All
patients were placed on their preoperative anticoagulation
regimen on day 1 or 2 postoperatively. The type of valve
surgery performed was not significantly different between
the 2 groups, except that there were 10 (15.3%) double
valve operations in the hybrid group and none in the con-
ventional group, with the difference in the numbers of aortic
valve replacements with mitral valve repairs reaching statis-
tical significance (P ¼ .025; Table 4).
In the hybrid group, of the 31 patients who had aortic
valve replacement, 29 (93.5%) were operated on for severe
aortic stenosis and 2 (6.4%) for prosthetic aortic valve re-
gurgitation. Of the 24 patients who had mitral valve surgery,ery c September 2012
TABLE 4. Type of valve surgery performed
Hybrid
(n ¼ 65)
Conventional
(n ¼ 52)
P
value
Aortic valve replacement alone 31 (47.7%) 32 (61.5%) .14
Mitral valve repair alone 14 (21.5%) 14 (28.8%) .37
Mitral valve replacement alone 10 (15.4%) 5 (9.6%) .36
Aortic valve replacement plus
mitral valve repair
6 (9.2%) 0 .025
Aortic valve replacement plus
mitral valve replacement
4 (6.2%) 0 .07
TABLE 5. Operative results
Variables
Hybrid
group
(n ¼ 65)
Conventional
group
(n ¼ 52)
P
value
In-hospital mortality 0 2 (3.8%) .11
Composite complications 1 (1.5%) 16 (38.8%) .001
ICU length of stay (h, median,
IQR)
50 (38-92) 98 (66-138) .001
Length of hospital stay
(d, median, IQR)
9 (7-12) 15 (10-20) .001
Units of PRBCs transfused
(mean  1 SD)
1.6  1.6 1.9  2.4 .35
Aortic crossclamp time
(min, median, IQR)
84.5 (71-108) 64 (47-92) .001
CPB time (min, median, IQR) 115 (96-135) 95 (78-115) .004
Prolonged ventilation 7 (10.7%) 22 (42.3%) <.001
Postoperative renal failure 1 (1.5%) 9 (17.3%) .002
Bleeding requiring
reoperation
1 (1.5%) 2 (3.8%) .43
Postoperative CVA 0 2 (3.8%) .11
Composite complications: mortality, renal failure, myocardial infarction, and cere-
brovascular accidents. Hybrid group hospital length of stay includes the length of
stay for the percutaneous coronary intervention. ICU, Intensive care unit; IQR, inter-
quartile range; PRBCs, packed red blood cells; SD, standard deviation; CPB, cardio-
pulmonary bypass; CVA, cerebrovascular accident.
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had myxomatous degeneration, and 5 (20.8%) had regurgi-
tation. The 10 patients who had aortic valve replacement
with mitral valve repair or replacement consisted of patients
with severe aortic stenosis, 6 of whom had mitral regurgita-
tion owing to calcific degeneration of the mitral valve and 4,
functional mitral regurgitation.
The median aortic crossclamp and cardiopulmonary by-
pass times for the hybrid group were 84.5 minutes (IQR,
71-108) and 115 minutes (IQR, 96-135), respectively; for
the conventional group they were 64 minutes (IQR, 47-
92) and 95 minutes (IQR, 78-115), P ¼ .001 and
P ¼ .004, respectively.
Clinical Outcomes
There were no deaths in the hybrid group, whereas the in-
hospital mortality for the conventional group was 2 (3.8%;
P ¼ .11). Of the 2 patients who died in the conventional
group, 1 did so from pneumonia/sepsis and the other died
of acute renal failure that was followed by an acute myocar-
dial infarction. Composite postoperative complications (re-
nal failure, stroke, myocardial infarction, or death) occurred
significantly less frequently in the hybrid group than in the
control group: 1 (1.5%) versus 16 (30.8%) (P¼ .001). The
incidence of prolonged intubation was 7 (10.7%) in the hy-
brid group and 22 (42.3%) in the median sternotomy group
(P< .001). The mean number of packed red blood cells
transfused in the hybrid group was 1.6  1.6 units and in
the conventional group, 1.9  2.4 units (P ¼ .35). There
was 1 (1.5%) reoperation for postoperative bleeding in
the hybrid arm compared with 2 in the conventional group
(P ¼ .43) (Table 5).
In the hybrid group, there were 41 patients taking clopi-
dogrel at the time of surgery and 24 who were not. Those
receiving clopidogrel required a mean of 1.9  1.8 units
of transfused packed red blood cells, whereas those not re-
ceiving clopidogrel required a mean of 1.4  1.5 units
(P ¼ .36).
Resource Use
The median length of stay in the intensive care unit was
50 hours (IQR, 38-92) for the hybrid group and 98 hoursThe Journal of Thoracic and Ca(IQR, 66-138) for the control group (P ¼ .001). The total
length of hospital stay, which included the hospital days
for the PCI interventions, was shorter in the hybrid group,
with a median of 9 days (IQR, 7-12) versus 15 days (IQR,
10-20) for the control group (P ¼ .001).DISCUSSION
A hybrid procedure that changes a conventional CABG
with concurrent valve surgery into a PCI with isolated min-
imally invasive valve surgery is an appealing way to parse
and minimize the risk of complex heart surgery. Our report
of a consecutive series of patients undergoing staged PCI
and minimally invasive valve surgery demonstrates a low
cumulative complication rate for the hybrid approach, cou-
pled with a short length of intensive care unit and overall
hospital stay. Indeed, a comparison with matched historical
controls at the same institution demonstrated the superiority
of the hybrid approach.
This hybrid approach was first evaluated by Byrne and
colleagues16 in a study of 26 patients with acute coronary
syndrome who underwent PCI followed by valve surgery
within a median of 5 days. The operative mortality was
3.8%, which was much lower than the 22% mortality pre-
dicted by the Society of Thoracic Surgeons Database. Be-
cause of the use of dual antiplatelet therapy, a high
incidence of bleeding occurred, with 22 (85%) of the 26 pa-
tients requiring blood transfusions. In an attempt to reduce
the incidence of bleeding, Brinster and colleagues20 per-
formed the PCI the day of, or evening before, the scheduledrdiovascular Surgery c Volume 144, Number 3 637
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There were no reoperations for bleeding, and only 8 (44%)
patients required blood transfusions. The hybrid patients in
our study had a lower number of blood transfusions than the
conventional group, but the difference did not reach statis-
tical significance. However, our study differs from the pre-
viously mentioned studies in that we had a significant
variation on the use of antiplatelet agents, which is a reflec-
tion of the different practice patterns among the interven-
tional cardiologists. We noted no difference in the need
for blood transfusions between the patients taking clopidog-
rel and those who were not taking it. On the basis of our
preliminary results, we recommend continuing dual antipla-
telet agents on the hybrid patients when they undergo min-
imally invasive valve surgery. The current guidelines for
antiplatelet management in patients with a bare metal coro-
nary stent who require surgery within 6 weeks of stent
placement is to continue aspirin and clopidogrel in the peri-
operative period, as well as in those who have had a drug-
eluding stent who require surgery within 12 months of stent
placement.21
As more hybrid PCI/valve procedures are being per-
formed, many questions remain unanswered, including
the optimal order for the procedures, their timing, the man-
agement of dual antiplatelet therapy, and the optimal costs
and logistics of the procedures.22 It would be reasonable
to hypothesize that the 1-stop approach proposed by Brin-
ster and colleagues20 not only reduces bleeding but also is
more convenient for the patient and more cost effective
than a 2-stage approach. This approach requires a high de-
gree of coordination between the interventional cardiologist
and the cardiothoracic surgeon, which may be facilitated by
the presence of a ‘‘hybrid’’ operating room designed for
performing both procedures.22 However, our experience
suggests that a hybrid approach combining PCI with mini-
mally invasive valve surgery can be done safely without
these special rooms.
Given the trends toward increases in minimally invasive
cardiac surgery, the broad applicability of the hybrid ap-
proach described here may be particularly appealing. Gam-
mie and colleagues23 reported that from 2004 to 2008 the
percentage of mitral valve operations that were done via
a minimally invasive approach increased from 11.9% to
20.1% (P<.0001). With this progression, it is most likely
that a hybrid approach will increase as well. On the other
hand, the short-term benefits of a hybrid approach are not
without potential long-term hazards. Clinical trials suggest
that, in many instances, full revascularization with coronary
surgery may be superior to partial revascularization with
PCI. Moreover, the long-term intervention-free survival of
a left internal thoracic graft to the left anterior descending
coronary artery is probably superior to the best currently
available drug-eluting stent. Thus, the results of this short-
term, single-center study should be viewed as supporting638 The Journal of Thoracic and Cardiovascular Surga prospective randomized controlled clinical trial to com-
pare a hybrid (staged) PCI and minimally invasive valve
surgery with the conventional median sternotomy approach.
Study Limitations
This was a single-center, retrospective study of a hetero-
geneous group of patients. All minimally invasive opera-
tions were performed by a single surgeon (J.L.). Selection
of patients for PCI was based on favorable anatomy for
this procedure, which is an important selection bias. The
follow-up of the patients was limited to 30 days, and thus
no statement may be made regarding long-term differences
in outcomes, as might be expected when comparing PCI and
CABG. Also, the control group and the study cohort were
not concurrent in terms of the time frames of the procedures
performed. The length of hospital stay in the conventional
patients was high at 15 days, which reflected patient recov-
ery times and clinical practice. These are uncontrollable
confounders, and in view of this, the results can only be in-
terpreted as hypothesis-generating.
CONCLUSIONS
In selected sites with a surgical team comfortable with
minimally invasive surgery, a staged approach of PCI fol-
lowed by minimally invasive valve surgery may be an effec-
tive approach for selected patients with suitable coronary
and valvular anatomy.
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